Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis.
Borand L, de Lauzanne A, Nguyen NL, Cheng S, Pham TH, Eyangoh S, Ouedraogo AS, Ung V, Msellati P, Tejiokem M, Nacro B, Inghammar M, Dim B, Delacourt C, Godreuil S, Blanche S, Marcy O; Pediatric Asian African Network for Tuberculosis and HIV Research (PAANTHER) Study Group. Borand L, et al. Among authors: nacro b. Clin Infect Dis. 2019 May 2;68(10):1750-1753. doi: 10.1093/cid/ciy897. Clin Infect Dis. 2019. PMID: 30689814 Free PMC article. Clinical Trial.
Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.
Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Urien S, Foulongne V, Van De Perre P, Tréluyer JM, Msellati P. Hirt D, et al. Among authors: nacro b. Antimicrob Agents Chemother. 2009 Oct;53(10):4399-406. doi: 10.1128/AAC.01187-08. Epub 2009 Jul 6. Antimicrob Agents Chemother. 2009. PMID: 19581461 Free PMC article. Clinical Trial.
Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S, Zoure E, Rouet F, Hien H, Msellati P, Van De Perre P, Tréluyer JM. Hirt D, et al. Among authors: nacro b. Antimicrob Agents Chemother. 2009 Oct;53(10):4407-13. doi: 10.1128/AAC.01594-08. Epub 2009 Jul 27. Antimicrob Agents Chemother. 2009. PMID: 19635964 Free PMC article. Clinical Trial.
Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Van De Perre P, Tréluyer JM, Msellati P, Urien S. Bouazza N, et al. Among authors: nacro b. Antimicrob Agents Chemother. 2010 Aug;54(8):3280-6. doi: 10.1128/AAC.00306-10. Epub 2010 Jun 1. Antimicrob Agents Chemother. 2010. PMID: 20516271 Free PMC article. Clinical Trial.
Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.
Nacro B, Zoure E, Hien H, Tamboura H, Rouet F, Ouiminga A, Drabo A, Yameogo S, Hien A, Peyriere H, Mathieu O, Hirt D, Treluyer JM, Nicolas J, Foulongne V, Segondy M, van de Perre P, Diagbouga S, Msellati P. Nacro B, et al. Bull World Health Organ. 2011 Jun 1;89(6):451-8. doi: 10.2471/BLT.10.081646. Epub 2011 Apr 6. Bull World Health Organ. 2011. PMID: 21673861 Free PMC article. Clinical Trial.
Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.
Barro M, Some J, Foulongne V, Diasso Y, Zouré E, Hien H, François R, Michel S, Drabo A, Tamboura H, Ouiminga A, Diagbouga S, Hien A, Yaméogo S, Van De Perre P, Nacro B, Msellati P. Barro M, et al. Among authors: nacro b. J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S44-9. doi: 10.1097/QAI.0b013e31821fd64f. J Acquir Immune Defic Syndr. 2011. PMID: 21857286 Clinical Trial.
AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.
Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Ménan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C; ANRS 12222 Morbidity/Mortality Study Group. Anglaret X, et al. Clin Infect Dis. 2012 Mar 1;54(5):714-23. doi: 10.1093/cid/cir898. Epub 2012 Feb 4. Clin Infect Dis. 2012. PMID: 22173233 Free PMC article.
Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis.
Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, Essex M, Ekouevi DK, Jackson D, Coutsoudis A, Kilewo C, Leroy V, Wiktor SZ, Nduati R, Msellati P, Zaba B, Ghys PD, Newell ML; UNAIDS Child Survival Group. Becquet R, et al. PLoS One. 2012;7(2):e28510. doi: 10.1371/journal.pone.0028510. Epub 2012 Feb 23. PLoS One. 2012. PMID: 22383946 Free PMC article.
Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.
De Beaudrap P, Boullé C, Lewden C, Gabillard D, Nacro B, Diagbouga S, Fassinou P, Hien H, Laurent C, Msellati P; ANRS 12222 Morbidity/Mortality Study Group. De Beaudrap P, et al. Among authors: nacro b. Pediatr Infect Dis J. 2013 Apr;32(4):354-60. doi: 10.1097/INF.0b013e318278b222. Pediatr Infect Dis J. 2013. PMID: 23099424
Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.
Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group. Gabillard D, et al. J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821. J Acquir Immune Defic Syndr. 2013. PMID: 23274931 Free PMC article.
63 results